|
๐
|
Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib.
20 auth.
D. Marin,
A. Bazeos,
F. Mahon,
L. Eliasson,
D. Milojkovic,
M. Bua,
J. Apperley,
Richard Szydlo,
R. Desai,
K. Kozlowski,
...
Christos Paliompeis,
V. Latham,
L. Foroni,
M. Molimard,
A. Reid,
K. Rezvani,
H. de Lavallade,
C. Guallar,
J. Goldman,
J. Khorashad
|
9 |
2010 |
9
๐
|
|
๐
|
In adults with standard-risk acute lymphoblastic leukemia, the greatest benefit is achieved from a matched sibling allogeneic transplantation in first complete remission, and an autologous transplantation is less effective than conventional consolidation/maintenance chemotherapy in all patients: fin
19 auth.
A. Goldstone,
S. Richards,
H. Lazarus,
M. Tallman,
G. Buck,
A. Fielding,
A. Burnett,
R. Chopra,
P. Wiernik,
L. Foroni,
...
E. Paietta,
M. Litzow,
D. Marks,
J. Durrant,
A. McMillan,
I. Franklin,
S. Luger,
N. Ciobanu,
J. Rowe
|
9 |
2006 |
9
๐
|
|
๐
|
Karyotype is an independent prognostic factor in adult acute lymphoblastic leukemia (ALL): analysis of cytogenetic data from patients treated on the Medical Research Council (MRC) UKALLXII/Eastern Cooperative Oncology Group (ECOG) 2993 trial.
18 auth.
A. Moorman,
C. Harrison,
G. Buck,
S. Richards,
L. Secker-Walker,
M. Martineau,
G. Vance,
A. Cherry,
R. Higgins,
A. Fielding,
...
L. Foroni,
E. Paietta,
M. Tallman,
M. Litzow,
P. Wiernik,
J. Rowe,
A. Goldstone,
G. Dewald
|
9 |
2005 |
9
๐
|
|
๐
|
Analysis of minimal residual disease by Ig/TCR gene rearrangements: guidelines for interpretation of real-time quantitative PCR data
19 auth.
V. Velden,
G. Cazzaniga,
A. Schrauder,
J. Hancock,
P. Bader,
E. Panzer-Gruฬmayer,
T. Flohr,
R. Sutton,
H. Cavรฉ,
H. Madsen,
...
J. Cayuela,
J. Trka,
C. Eckert,
L. Foroni,
U. Stadt,
K. Beldjord,
T. Raff,
C. E. Schoot,
J. Dongen
|
9 |
2007 |
9
๐
|
|
๐
|
Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia
14 auth.
A. Hochhaus,
S. OโBrien,
F. Guilhot,
B. Druker,
S. Branford,
L. Foroni,
J. Goldman,
M. Muฬller,
J. Radich,
M. Rudoltz,
...
M. Mone,
I. Gathmann,
T. Hughes,
R. Larson
|
8 |
2009 |
8
๐
|
|
๐ข
|
Assessment of BCR-ABL1 transcript levels at 3 months is the only requirement for predicting outcome for patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors.
16 auth.
D. Marin,
Amr Ibrahim,
C. Lucas,
G. Gerrard,
Lihui Wang,
Richard Szydlo,
R. Clark,
J. Apperley,
D. Milojkovic,
M. Bua,
...
J. Pavlลฏ,
Christos Paliompeis,
A. Reid,
K. Rezvani,
J. Goldman,
L. Foroni
|
8 |
2012 |
8
๐ข
|
|
๐
|
Chromosomally unstable mouse tumours have genomic alterations similar to diverse human cancers
36 auth.
R. Maser,
Bhudipa Choudhury,
Peter J. Campbell,
Bin Feng,
Kwok-kin Wong,
A. Protopopov,
J. O'neil,
A. Gutierrez,
E. Ivanova,
I. Perna,
E. Lin,
Vidya Mani,
Shan Jiang,
K. McNamara,
Sara Zaghlul,
...
S. Edkins,
C. Stevens,
C. Brennan,
E. Martin,
R. Wiedemeyer,
O. Kabbarah,
C. Nogueira,
G. Histen,
J. Aster,
M. Mansour,
V. Duke,
L. Foroni,
A. Fielding,
A. Goldstone,
J. Rowe,
Y. A. Wang,
A. Look,
Michael R. Stratton,
L. Chin,
P. Futreal,
R. DePinho
|
8 |
2007 |
8
๐
|
|
๐
|
Stereotyped B-cell receptors in one-third of chronic lymphocytic leukemia: a molecular classification with implications for targeted therapies.
36 auth.
A. Agathangelidis,
N. Darzentas,
A. Hadzidimitriou,
Xavier Brochet,
F. Murray,
Xiao-Jie Yan,
Z. Davis,
E. J. van Gastel-Mol,
C. Tresoldi,
C. Chu,
N. Cahill,
V. Giudicelli,
B. Tichy,
L. Pedersen,
L. Foroni,
...
L. Bonello,
A. Janus,
K. Smedby,
A. Anagnostopoulos,
H. Merle-Bรฉral,
Nikolaos Laoutaris,
G. Juliusson,
P. F. di Celle,
ล . Pospรญลกilovรก,
J. Jurlander,
C. Geisler,
A. Tsaftaris,
M. Lefranc,
A. Langerak,
D. Oscier,
N. Chiorazzi,
C. Belessi,
F. Davi,
R. Rosenquist,
P. Ghia,
K. Stamatopoulos
|
8 |
2012 |
8
๐
|
|
๐ฌ
|
The rhombotin family of cysteine-rich LIM-domain oncogenes: distinct members are involved in T-cell translocations to human chromosomes 11p15 and 11p13.
T. Boehm,
L. Foroni,
Y. Kaneko,
M. Perutz,
T. Rabbitts
|
8 |
1991 |
8
๐ฌ
|
|
๐
|
European LeukemiaNet criteria for failure or suboptimal response reliably identify patients with CML in early chronic phase treated with imatinib whose eventual outcome is poor.
15 auth.
D. Marin,
D. Milojkovic,
E. Olavarrรญa,
J. Khorashad,
H. de Lavallade,
A. Reid,
L. Foroni,
K. Rezvani,
M. Bua,
F. Dazzi,
...
J. Pavlลฏ,
M. Klammer,
J. Kaeda,
J. Goldman,
J. Apperley
|
8 |
2008 |
8
๐
|
|
๐
|
Regulation of myeloid leukemia by the cell fate determinant Musashi
19 auth.
Takahiro Ito,
H. Kwon,
Bryan Zimdahl,
Kendra L Congdon,
Jordan M. Blum,
William E. Lento,
Chen Zhao,
A. Lagoo,
G. Gerrard,
L. Foroni,
...
J. Goldman,
Harriet Goh,
Soo-hyun Kim,
Dong-Wook Kim,
C. Chuah,
V. Oehler,
J. Radich,
C. Jordan,
T. Reya
|
8 |
2010 |
8
๐
|
|
๐
|
UKALLXII/ECOG2993: addition of imatinib to a standard treatment regimen enhances long-term outcomes in Philadelphia positive acute lymphoblastic leukemia.
15 auth.
A. Fielding,
J. Rowe,
G. Buck,
L. Foroni,
G. Gerrard,
M. Litzow,
Hillard J. Lazarus,
S. Luger,
D. Marks,
A. McMillan,
...
A. Moorman,
B. Patel,
E. Paietta,
M. Tallman,
A. Goldstone
|
8 |
2014 |
8
๐
|
